Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough

Trial Profile

A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefapixant (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Sponsors Afferent Pharmaceuticals
  • Most Recent Events

    • 29 Sep 2020 Number of treatment arms has been increased from 2 to 4, dividing the enrolled patients into 2 cohorts-- cohort 1 and 2 and further dividing both these cohorts into 2 groups namely- Gefapixant greater than Placebo and Placebo greater than Gefapixant- comprising different doses of the primary drug. The total number of primary end-points has been increased to 6.
    • 16 Mar 2020 Results evaluating comorbid conditions and secondary diagnoses associated with cough using two phase II trials (NCT02349425 and NCT02612610) presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 16 Jan 2020 Results evaluating the dose response of gefapixant in reducing awake objective cough frequency and identifying tolerable doses through the evaluation of low and high-dose cohorts using 2 randomised , double blind, placebo contolled trials published in the European Respiratory Journal
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top